A share price of Pyxis Oncology Inc [PYXS] is currently trading at $1.32, up 8.20%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PYXS shares have gain 6.45% over the last week, with a monthly amount glided 4.76%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Pyxis Oncology Inc [NASDAQ: PYXS] stock has seen the most recent analyst activity on November 21, 2024, when William Blair downgraded its rating to a Mkt Perform. Previously, Stephens started tracking the stock with Overweight rating on November 08, 2024, and set its price target to $13. On August 08, 2024, Stifel initiated with a Buy rating and assigned a price target of $10 on the stock. BTIG Research initiated its recommendation with a Buy and recommended $8 as its price target on February 09, 2024. Leerink Partners started tracking with a Outperform rating for this stock on January 23, 2024, and assigned it a price target of $12. In a note dated September 05, 2023, RBC Capital Mkts initiated an Outperform rating and provided a target price of $7 on this stock.
Pyxis Oncology Inc experienced fluctuations in its stock price throughout the past year between $0.83 and $5.39. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Pyxis Oncology Inc [NASDAQ: PYXS] shares were valued at $1.32 at the most recent close of the market. An investor can expect a potential return of 581.82% based on the average PYXS price forecast.
Analyzing the PYXS fundamentals
Trailing Twelve Months sales for Pyxis Oncology Inc [NASDAQ:PYXS] were 0.00M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at 0.33% with Operating Profit Margin at -31.38%, Pretax Profit Margin comes in at -28.63%, and Net Profit Margin reading is -27.99%. To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -0.7 and Total Capital is -0.88. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2367 points at the first support level, and at 1.1533 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3717, and for the 2nd resistance point, it is at 1.4233.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Pyxis Oncology Inc [NASDAQ:PYXS] is 7.75. Also, the Quick Ratio is 7.75, while the Cash Ratio stands at 0.88.
Transactions by insiders
Recent insider trading involved HUMPHREY RACHEL, Director, that happened on Apr 21 ’25 when 13896.0 shares were purchased. Director, HUMPHREY RACHEL completed a deal on Apr 17 ’25 to buy 200.0 shares. Meanwhile, Director HUMPHREY RACHEL bought 1400.0 shares on Apr 14 ’25.
